BeiGene reports Q1 GAAP EPS 1c, consensus (74c)

Reports Q1 adjusted EPS $1.22. Reports Q1 revenue $1.1B, consensus $1.14B. “We delivered another exceptional quarter, achieving our first quarter of GAAP profitability with continued global revenue growth. In the U.S., BRUKINSA remains the leader in new chronic lymphocytic leukemia (CLL) patient starts across all lines of therapy, and for the first time has become the overall BTKi market share leader,” said CEO John V. Oyler. “We’ve made significant strides across our late-stage hematology and solid tumor pipelines, with multiple proof-of-concept readouts expected this year across our broad portfolio of antibody-drug conjugates, multispecific antibodies and targeted protein degraders. With accelerating financial momentum and a diversified global footprint spanning six continents, we are well positioned – as we transition to BeOne Medicines and redomicile to Switzerland – to become one of the world’s most impactful oncology innovators.”